BAXDELA (delafloxacin meglumine) by CorMedix is 12. Approved for skin structure infections (absssi) caused by the following susceptible microorganisms: staphylococcus aureus (including methicillin-resistant [mrsa], methicillin-susceptible [mssa] isolates), staphylococcus haemolyticus and 17 more indications. First approved in 2017.
Drug data last refreshed 22m ago · AI intelligence enriched 6d ago
BAXDELA (delafloxacin meglumine) is a fluoroquinolone antibacterial approved in 2017 for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive and Gram-negative organisms including MRSA. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, with efficacy correlating to the fAUC/MIC ratio. The drug is available as an oral tablet with 58.8% bioavailability and achieves steady-state within three days.
Product is at peak lifecycle stage with stable commercial operations, suggesting mature team size and focus on market maintenance rather than rapid expansion.
12.1 Mechanism of Action BAXDELA is an antibacterial drug [see ] . 12.2 Pharmacodynamics The antibacterial activity of delafloxacin appears to best correlate with the ratio of area under the concentration-time curve of free delafloxacin to minimal inhibitory concentration ( f AUC/MIC) for…
Worked on BAXDELA at CorMedix? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~5 years — strategic planning for patent cliff underway
Working on BAXDELA offers exposure to peak-stage lifecycle management in a competitive antibiotic market, requiring strong competitive positioning and payer negotiation skills. Career trajectory is likely stable but constrained by modest spending ($0–$16M range among competitors) and 5-year patent exclusivity window, making this suitable for professionals seeking mature-market experience rather than high-growth trajectory.